Whatever Happened to Up-Front Equity?
Executive Summary
In the past, in-licensers of biotech products often turned to up-front equity purchases, rather than cash licensing payments, to help defray P&L costs of licensing. The partner received the same money to fund its research, the rationale went, and the licensee could book at least some of the payment as the acquisition of an asset, rather than an R&D expense. But as In Vivo amply demonstrates, that thinking is so 20th Century. While equity payments often made up more than half the total paid up front in biotech licensings throughout the 1990's, they've fallen to 25% or below, since 2002.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.